- What is RARE's revenue?
- Ultragenyx Pharmaceutical Inc. (RARE)'s most recent annual revenue is $673.0 million for fiscal year 2025 (ended December 31, 2025). The full 10+ year revenue history and quarterly trend are in the Revenue card on this page; analyst forecasts for the next 1–2 fiscal years are in the forward-revenue card below.
- How is RARE's revenue growing?
- Ultragenyx Pharmaceutical Inc.'s most recent year-over-year revenue growth was 20.1%. The Revenue card on this page shows the full history with a 5-year CAGR for context; the quarterly view reveals recent acceleration or deceleration.
- What is RARE's gross margin?
- Ultragenyx Pharmaceutical Inc. (RARE)'s most recent annual gross margin is 83.8%. The Margins cascade chart on this page layers gross / operating / net margins together with year-over-year direction — one of the strongest signals for the underlying unit economics.
- What is RARE's net income?
- Ultragenyx Pharmaceutical Inc.'s most recent annual net income — total earnings after all expenses, interest, and taxes — was $-575.0 million for fiscal year 2025 (ended December 31, 2025). Annual + quarterly views, growth rate, GAAP vs non-GAAP, and per-share figures are all in the Net Income card on this page.
- How current is RARE's income statement data?
- The income-statement figures for Ultragenyx Pharmaceutical Inc. (RARE) on this page are as of fiscal year 2025 (ended December 31, 2025). New 10-Q (quarterly) and 10-K (annual) filings are typically parsed and reflected here within 48 hours of SEC submission.
